Informed Prostate Cancer Patient Support

Prostatepedia Digest 12.31.2020

Comparative Effectiveness Research in Localized Prostate Cancer: a 10-Year follow-up Cohort Study - International Journal of Radiation Oncology, Biology, Physics

PSMA Imaging by PET/CT Cost Effective vs Conventional Imaging

Cancer Survivors at Greater Risk for Subsequent Malignancies | MedPage Today

Geography Seen as Factor in Overtreatment of Low-Risk Prostate Cancer | MedPage Today

Cancer Treatment Delays Are Deadly: 5- and 10-Year Data

2020-12-18-MLNC-SE | CMS

Survival with Provenge - Real World Data Along with a Peak Into the Future of Treatment

Whole pelvic salvage radiation may be better than precisely targeted lymph node salvage radiation | THE "NEW" PROSTATE CANCER INFOLINK

Prostate cancer regulator plays role in COVID-19, providing a promising treatment lead -- ScienceDaily

Targeting bone metastases with radiation in oligorecurrent men has no survival benefit in Mayo study | THE "NEW" PROSTATE CANCER INFOLINK

FDA OKs First Oral ADT for Prostate Cancer | MedPage Today

FDA approves first, oral LHRH antagonist | THE "NEW" PROSTATE CANCER INFOLINK

Prostatepedia Digest 12.18.2020

New high-resolution imaging scans approved for use in prostate cancer - Harvard Health Blog - Harvard Health Publishing

Prostate Cancer Updates With Dr. Tanya Dorff and Dr. Sumanta Pal—PracticeUpdate's ESMO 2016 Coverage - YouTube

PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study | Journal of Nuclear Medicine

The Prognostic Value of Quantitative Bone SPECT/CT Before 223Ra Treatment in Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine

Scientific Retreat - Reports | Prostate Cancer Foundation

New Scan Finds Prostate Cancer Cells Hiding in the Body - The New York Times

Androgen receptor signaling‐targeted therapy and taxane chemotherapy induce visceral metastasis in castration‐resistant prostate cancer - Iwamoto - 2021 - The Prostate - Wiley Online Library

The 26th Annual Prostate Cancer Foundation Scientific Retreat Report - Miyahira - 2021 - The Prostate - Wiley Online Library

The characteristics and spatial distributions of prostate cancer in autopsy specimens - Zhou - - The Prostate - Wiley Online Library

Targeting bone metastases with radiation in oligorecurrent men has no survival benefit in Mayo study | THE "NEW" PROSTATE CANCER INFOLINK

Influence of Geography on Prostate Cancer Treatment - ScienceDirect

SB 452 - Cancer Registry Patient Notification | Senator Brian Jones

Influence of Geography on Prostate Cancer Treatment - International Journal of Radiation Oncology, Biology, Physics

The characteristics and spatial distributions of prostate cancer in autopsy specimens - Zhou - - The Prostate - Wiley Online Library

Prostatepedia Digest 12.11.2020

High-Risk Prostate Cancer Patients Can Wait 6 Months for Surgery: Study | MedPage Today

Manufacture and use of gallium-68 PSMA-11 for PET/CT scans | THE "NEW" PROSTATE CANCER INFOLINK

Prostatepedia Digest 12.5.2020

Radiation Rx for Prostate Cancer Can Cause Financial Pain: Study : People diagnosed with cancer often have many concerns, including financial toxicity, the hardship and stress associated with the cost of treatment.

Clinical Challenge: Test Your Knowledge of Prostate Cancer | MedPage Today

Early‐onset prostate cancer is associated with increased risks of disease progression and cancer‐specific mortality - Shih - - The Prostate - Wiley Online Library

Genetics, epigenetics, and the evolution of prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK

Prostate Cancer Progression and the Epigenome | NEJM

Androgen-Deprivation Therapy Linked to Worse Fitness, CV Mortality

Clinical Challenges: Can MRI and Biomarkers Replace Biopsy for AS in Prostate Cancer? | MedPage Today

Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience | Prostate Cancer and Prostatic Diseases

FDA approves first gallium-68 PSMA PET scan imaging agent in US, BUT … | THE "NEW" PROSTATE CANCER INFOLINK

FDA Approves First Agent for PSMA-PET Imaging in Prostate Cancer

Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience | Prostate Cancer and Prostatic Diseases

Drug reverses age-related mental decline within days, mouse study shows: Rapid rejuvenation of mental faculties in aged mice implicates reversible physiological 'blockage' behind age-related cognitive losses -- ScienceDaily

FDA OKs 'Game Changer' Radiotracer for Prostate Cancer | MedPage Today

FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer | FDA

FDA Approves Gallium 68 PSMA-11 as PET-Imaging Drug for Prostate Cancer

Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial

177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer

Semiautomatically Quantified Tumor Volume Using 68Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer